For metastatic castration-sensitive prostate cancer (mCSPC), overall survival (OS) and progression-free survival (PFS) are similar for Black and White patients receiving firstor second-generation androgen receptor pathway inhibitors within a clinical trial, according to a study published in JAMA Network Open. Nicolas Sayegh, MD, and colleagues conducted a secondary analysis of patient-level data of a prospective phase 3 randomized clinical trial including patients with newly diagnosed mCSPC to compare survival outcomes by race. Patients receiving androgen deprivation therapy were randomly assigned to receive orteronel 300 mg orally twice daily (experimental group) or bicalutamide 50 mg orally daily (control group). Data were included for 1,313 participants: 10% and 82% identified as Black and White, respectively, with an equal racial distribution between the treatment groups. Black and White patients had similar median PFS (2.3 years vs 2.9 years) and OS (5.5 years vs 6.3 years) at a median follow-up of 4.9 years. After adjustment for known prognostic factors, the multivariable analysis confirmed similar PFS and OS. ere was no interaction observed between race and treatment.
